基于结构的共价SARS-CoV-2主要蛋白酶抑制剂的设计,针对耐尼马特里尔维尔抗性E166突变物
Zhengjun Cai1, Navita Kohaal2, Kyriakos Georgiou3
1Department of Medicinal Chemistry, Ernest Mario School of Pharmacy, Rutgers, the State University of New Jersey, Piscataway, New Jersey 08854, United States.
一种新的候选药物Jun13698有效地抑制了SARS-CoV-2的主要蛋白酶 (Mpro),包括耐药变种. 这一发展提供了一种对抗COVID-19耐药性的有希望的策略.
科学领域:
- 病毒学 病毒学
- 药物发现 药物发现 药物发现
- 生物化学 生物化学
背景情况:
- 由于COVID-19大流行,需要快速开发抗病毒药物,因此尼尔马特里尔维尔 (主要的蛋白酶抑制剂) 成为关键治疗方法.
- 新兴的耐药性,特别是Mpro E166V突变,对当前和未来的COVID-19疗法构成重大威胁.
- 这种突变赋予了对几种下一代Mpro抑制剂的交叉耐药性.
研究的目的:
- 合理设计和开发新型主要蛋白酶抑制剂,有效对抗耐尼尔马特里尔维尔抗性SARS-CoV-2变种.
- 确定一种可以克服临床相关药物耐药性的主要候选化合物.
主要方法:
- 合理的药物设计原则被应用来创建向Mpro. 向的抑制剂.
- 实验室酶定试验被用来评估对野生类型和突变Mpro.对抑制剂的强度.
- 使用结构研究和分子动力学模拟来了解抑制剂-蛋白酶相互作用.
- 在基于细胞的测试中评估了抗病毒活性.
主要成果:
- 主要候选者Jun13698对野生型Mpro和对E166V/A耐药突变体都表现出强大的抑制作用.
- 结构和模拟数据证实了Jun13698和野生类型和突变蛋白酶之间的稳定复合体形成.
- Jun13698表现出强大的酶和抗病毒活性,与其结构稳定性一致.
结论:
- Jun13698是一种有前途的下一代主要蛋白酶抑制剂.
- 这种化合物有效地克服了由Mpro E166V/A突变介导的临床相关的涅马特雷尔维尔耐药性.
- Jun13698代表了管理耐药COVID-19的潜在治疗选择.
更多相关视频
07:13Swabbing the Urban Environment - A Pipeline for Sampling and Detection of SARS-CoV-2 From Environmental Reservoirs
Published on: April 9, 2021
06:08Author Spotlight: A Pseudotype Virus System for Assessing Omicron Subvariants and Neutralizing Antibodies in SARS-CoV-2 Research
Published on: September 8, 2023
相关概念视频
Covalent Bonding and Lewis Structures
Design Example: Resistive Touchscreen
When a user touches the screen, the two layers make contact at a specific point known as the touchpoint. This contact reduces the resistance between...
Network Covalent Solids
To break or to melt a covalent network solid, covalent bonds must be broken. Because covalent bonds are relatively strong, covalent network solids are typically...
Covalent Bonds
Covalent Bonds
When two atoms share electrons to complete their valence shells, they create a covalent bond. An atom's electronegativity—the force with which shared electrons are pulled towards an atom—determines how the electrons are shared. Molecules formed with covalent bonds can be either polar or nonpolar. Atoms with similar electronegativities form nonpolar covalent bonds; the electrons are shared equally. Atoms with different electronegativities share electrons unequally,...
Covalently Linked Protein Regulators
These groups modify specific amino acids in a protein....
